Connection

Robert Schooley to Anti-HIV Agents

Back to Details
This is a "connection" page, showing publications Robert Schooley has written about Anti-HIV Agents.
Robert Schooley
Connection Strength
0.351
Anti-HIV Agents
  1. Linked dual-class HIV resistance mutations are associated with treatment failure. JCI Insight. 2019 10 03; 4(19).
    View in: PubMed
    Score: 0.080
  2. Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor. Molecules. 2018 Nov 20; 23(11).
    View in: PubMed
    Score: 0.076
  3. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
    View in: PubMed
    Score: 0.075
  4. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151.
    View in: PubMed
    Score: 0.071
  5. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012; 9(6):e1001236.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.